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design of this study is a cross sectional study using secondary
data. The sampling frame will include high school students. The
method of sample selection used is the clustering sampling
method. The unit of analysis is at the individual level. The study
population is high school students. The dependent variable is
weight and independent variables are: height, diet, nutrition,
exercising, age, sex, race and self-perception. RESULTS: The
model was very representational of the study population r2 =
0.584. The statistical signiﬁcance level was 0.05 and many vari-
ables (Height, Gender, Ethnicity, Age, etc.) proved to have a
strong signiﬁcant affect on weight (Beta was also used). CON-
CLUSIONS: The limitation of the study is that the survey fails
to ask any question regarding genetic disorders that inﬂuence
excessive weight gain, obesity. This information would be
formable in trying to treat adolescents who currently suffer from
genetic disorders. Also this would provide a good estimate of the
percentage of young people (by ethnicity) who are affected.
Another survey is recommended; that ask an assortment of ques-
tions pertaining to the daily habits of adolescents, a social behav-
ioral study. The information could aid in the development of a
better behavioral treatment for children in accordance to their
life style. The Youth Risk Behavioral Survey needs to be modi-
ﬁed so that it is more inclusive. The survey should be translated
into other languages and made available for students who are
not ﬂuent in comprehending English. Non-English speaking 
children do gain weight as well.
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OBJECTIVES: The HF-ACTION trial evaluates the effectiveness
of exercise as an intervention for heart failure patients. To assess
generalizability of study ﬁndings, we included a survey of par-
ticipating site characteristics as part of the study. We hypothe-
sized that rates of Medicare managed care penetration would
inﬂuence site heart failure care strategies. METHODS: Survey
items were developed based on a literature review and clinicians’
input. Sites were divided into high- and low-penetration groups
according to their counties’ rates of Medicare managed care pen-
etration. Rates were obtained from the Centers for Medicare and
Medicaid Services, and high- and low-penetration categories
were delineated by the sample median. Simple statistics were
used to describe the sample. Wilcoxon rank-sums and ∏ 2 tests
were used to test for differences between areas of high and low
managed care penetration. RESULTS: We received 47 of 50
surveys, a response rate of 94%. We found considerable varia-
tion in the availability of certain resources between areas of low
and high managed care penetration. Institutions located in high-
penetration areas were more likely than those in low-penetration
areas to treat heart failure outpatients in geriatric clinics (100%
vs. 0%, p = 0.014), to have IV diuretics available in clinic (100%
vs. 80%, p = 0.049) and to use clinics for acute care (40% vs.
11%, p = 0.044). Availability of heart failure service (96% vs.
79%, p = 0.057), availability of nutritionist in clinic (45% 
vs. 74%, p = 0.069) and use of ER for acute care episodes (85%
vs. 61%, p = 0.095) also varied by degree of managed care pen-
etration. Use of BNP blood test did not vary signiﬁcantly in inpa-
tient (high—39% vs. low—58%, p = 0.210) or outpatient
settings (50% vs. 47%, p = 0.860). CONCLUSIONS: Our
assessment in a clinical trial setting suggests that available
resources vary by degree of managed care penetration. This 
variability should be considered when analyzing the HF-
ACTION data as it could affect patient care and outcomes.
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GASTRIC BYPASS SURGERY—AN OVERVIEW
Misra S
Rush University Medical Center, Chicago, IL, USA
OBJECTIVE: Evaluating gastric bypass surgery in obese
patients. METHODS: From March 1999 to December 2002,
106 obese patients underwent gastric bypass operations by a
single surgeon in a tertiary care hospital in the Midwest. The
data is extracted from the clinical charts and evaluated statisti-
cally using SPSS software. The relationship between body mass
index (BMI) of patients, type of operation performed, operating
time, length of stay (LOS) in the hospital, presence of co-mor-
bidities and payer type are analyzed. RESULTS: Fifty-six and 51
patients underwent open and laparoscopic bypass surgeries
respectively. The mean BMI is 53.96 with minimum of 36.1 and
maximum of 85.2 with the mean overall LOS being 4.22 days
with minimum of 2 and maximum 28 days. The mean LOS for
open and laparoscopic gastric bypass surgery is 5 and 3 days
respectively. The mean operating time for the open and laparo-
scopic methods are 165 and 175 minutes respectively. LOS is
positively correlated with BMI (p < 0 .05, r = 0.248), the number
of pre-existing medical conditions (p < 0.05, r = 0.218), open
surgery (p < 0.01, r = 0.323) but negatively correlated with
laparoscopic surgery (p < 0.01, r = -0.306) while intensive care
usage is positively correlated with BMI and open surgery (p <
0.01, r = 0.350 and 0.250) but is negatively correlated with
laparoscopic procedures (p < 0.01, r = -0.266). Pulse rates
greater than 110/minute on second and third post-operative days
is associated with total operating time (p < 0.01, r = 0.370) and
with post-operative leak from anastomosis on ﬁrst and third
post-operative days (p < 0.05 and 0.01, r = 0.228 and 0.272)
respectively. BMI is also positively associated with public 
aid patients but is negatively associated with private payers.
CONCLUSION: Being an increasingly popular surgery for 
obese people, gastric bypass procedures need to be carefully 
evaluated long-term for optimum clinical and economic out-
comes in view of the above ﬁndings.
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OBJECTIVE: Beta-blocker utilization in patients with mild to
moderate congestive heart failure (CHF) substantially improves
left ventricular ejection fraction and patient symptoms and
reduces overall mortality. Carvedilol and extended-release meto-
prolol succinate are the only beta-blocking agents currently indi-
cated in the US for CHF patients. Both agents have shown similar
risk reduction in overall and cause-speciﬁc mortality; however,
no comparative outcomes data for the two agents are available.
This study identiﬁes current utilization patterns (agent/dosing
regimens) of beta-blocker therapy in the CHF population at Scott
& White Health Plan. METHODS: Health plan pharmacy
claims data were retrospectively reviewed for calendar year 2002
for beta-blocker prescribing patterns for CHF patients (identi-
ﬁed by ICD-9 codes). Speciﬁcally, pharmacy claims were evalu-
ated for inclusion of beta-blockers as standard therapy for CHF,
use of FDA-approved versus off-label use of beta-blockers for
CHF, and use of recommended doses. RESULTS: Approximately
1700 health plan CHF patients were identiﬁed; 40% of those
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patients had a prescription ﬁlled for a beta-blocker during 2002.
Of the CHF patients receiving a beta-blocker, less than 45% were
prescribed either of the two indicated agents (carvedilol or
extended-release metoprolol succinate) for CHF. Furthermore,
less than 40% of patients prescribed either carvedilol or
extended-release metoprolol succinate achieved target CHF
doses. Thus, of those CHF patients currently on beta-blocker
therapy, less than 17% received an appropriate regimen. CON-
CLUSIONS: This evaluation illustrates that less than ten percent
of CHF patients in this managed care plan are receiving optimal
beta-blocker therapy. Future quality improvement efforts should
be focused on provider-based educational initiatives to improve
beta-blocker prescribing patterns in the CHF population.
Increased use of beta-blocker therapy in patients identiﬁed with
CHF would signiﬁcantly improve the morbidity and mortality
associated with this disease.
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OBJECTIVES: To investigate statin usage patterns in terms of
termination, switch and/or augmentation, and to associate these
patterns with changing market conditions. METHODS: The
study is based on a 20% sample of California Medicaid (Medi-
Cal) fee-for-service claims on statin prescriptions from 1995
through 2002. The length of the ﬁrst statin therapy phase is pre-
sented with Kaplan-Meier curves. The switch and/or augmenta-
tion pattern is studied by tracking each patient for 12 months
from the date of the ﬁrst ﬁll (index date). Results are presented
by the year of index date. There are six statins included in the
study: Cerivastatin, Fluvastatin, Atorvastatin, Lovastatin,
Pravastatin and Simvastatin. RESULTS: Atorvastatin (N =
15,686, Median survival days = 244) and Simvastatin (N = 9162,
Median survival days = 200) had longer therapy phases while
Cerivastatin (N = 2022, Median survival days = 101) and Lovas-
tatin (N = 8910, Median survival days = 99) had shorter therapy
phases. About 40% of Atorvastatin and Simvastatin patients
were still on their initial medication after one year, but only 20%
of patients initiated on Lovastatin or Cerivastatin remained on
their medication. The introduction of Atorvastatin was associ-
ated with a sudden increase of switch/augmentation events
among patients initiated on other statin brands. When Cerivas-
tatin was withdrawn from the US market and Lovastatin was
phased out of the Medi-Cal formulary, the proportion of
switch/augmentation events also increased. CONCLUSIONS:
The introduction of Atorvastatin, the withdrawal of Cerivastatin
and the phase-out of Lovastatin may be key factors in statin per-
sistence patterns. Market forces should not be overlooked when
analyzing medication compliance and medication usage patterns.
Because changes in the market are more likely to be unique
events, their effect may overshadow other adjustments in 
comparison of medication compliance.
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ON PHYSICIAN PRESCRIBING PATTERNS AND PATIENT
UTILIZATION OF ANTIHYPERTENSIVE MEDICATIONS
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OBJECTIVES: To analyze the changes in utilization and pre-
scribing patterns of antihypertensive drugs before and after the
publication of the ALLHAT results in 2002 that recommended
the use of thiazide diuretics in new starts. METHODS: Utilizing
pharmacy claims, member and provider data from a managed
care plan of over 2 million members, this study selected two
cohorts of patients who received two or more claims for anti-
hypertensive or diuretic products from the same providers in the
ﬁrst 9 months of 2002 (Period 1) or the ﬁrst 9 months of 2003
(Period 2). The providers who prescribed antihypertensive or
diuretic medications for both periods were included. The patients
were continuously enrolled adults who did not receive any anti-
hypertensive or diuretic products in the 3 months prior to index
date. Changes in physician prescribing patterns for initiation of
hypertension treatment in Period 1 and Period 2 were analyzed.
Utilization of different medications between the two periods,
especially the likelihood of receiving thiazide diuretics, was also
examined. RESULTS: The study identiﬁed 7605 physicians who
prescribed antihypertensive drugs to 25,519 patients in Period 1
and 26,300 patients in Period 2. Across the two periods, the per-
centage of physicians who prescribed any thiazide diuretics
increased from 14.5% to 16.1% (p < 0.01), while utilization of
ACE inhibitors or CCBs as initial treatment decreased approxi-
mately 2% (p < 0.01). A logistic regression model indicated that
patients in Period 2 were 22.8% more likely to receive thiazide
diuretics and 9.9% more likely to receive any diuretics than
patients in Period 1 (p < 0.01), controlling for demographics,
comorbidities measured by chronic disease scores (CDS), 
and provider specialties. CONCLUSION: ALLHAT results
increased prescribing of thiazide diuretics as initial treatment of
hypertension.
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OBJECTIVE: The NSF guidelines for CAD, introduced in March
2000 in the UK, advocate that by April 2002, 80–90% of the
patients discharged from hospital following myocardial infarc-
tion (MI) should be receiving prescriptions for aspirin and statins
for secondary prevention. A time-trend analysis was performed
to assess the impact of NSF on physician compliance with the
prescribing guidelines. METHODS: The UK-Mediplus, a nation-
ally representative general-practitioner database was used to
identify all individuals with diagnosis of their ﬁrst MI (index-
date) between April 1997 and March 2003, and surviving at least
90 days following the index-date. Patients receiving at least one
prescription of statin and aspirin, linked to their MI diagnosis,
during the 90-day follow-up period were considered NSF-com-
pliant with those drugs respectively. Annual trends in proportion
of NSF-compliant patients, for aspirin, statins and aspirin-statin
combination, were compared between pre- and post-NSF (after
March 2000) periods. Logistic regression was used to estimate
the effect of age and gender on compliance. RESULTS: Of 8598
eligible ﬁrst-MI patients with a mean age of 70.4 (S.D. = 13.2),
65.5% were males, and 67.2% were elderly (age 65+). Aspirin-
statin combination use increased from 13.7% to 23.5% between
April 1997 and March 2000, and increased to 42.1% by March
2003. Aspirin and statin use alone were 49.5% and 71.6%
respectively by end of March 2003. Relative to non-elderly, the
elderly were less likely to receive aspirin-statin combination.
However, the odds ratio (OR) for the elderly receiving combi-
nation improved during post-NSF period (OR = 0.64, p < 0.05
